Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy

Huang Zhu, Dan S. Kaufman*
Division of Regenerative Medicine, Department of Medicine, University of California San Diego, San Diego, CA, USA

Abstract
Adoptive immunotherapy using immune effector cells has revolutionized cancer treatments with approval of two autologous chimeric antigen receptor (CAR) T cell therapies by the US FDA. Clinical trials using natural killer (NK) cell-based adoptive immunotherapy have been shown to be safe and effective for treatment of multiple malignancies, especially acute myelogenous leukemia. However, most of these trials use primary NK cells isolated from peripheral or cord blood which can have donor-dependent variability and can be challenging to genetic engineer to improve antitumor functions, limiting the widespread use of this promising new therapy. NK cells can now be routinely produced from human pluripotent stem cells, both human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs). These pluripotent stem cells are homogenous, easy to genetically modify on a clonal level and can be used as unlimited source of NK cells, making them ideal population to develop standardized, off-the-shelf adoptive NK cell therapy products. In this review, we discuss recent advances of obtaining and expanding hESC and iPSC-derived NK cells and novel genetic engineering strategies that are being applied to improve their antitumor functions.

Keywords: Adoptive NK cell therapy, Cancer immunotherapy, CAR-NK cells, Chimeric antigen receptor, Human stem cells, Natural killer cells

1. INTRODUCTION
Adoptive cell therapy has emerged as novel and promising treatment option for relapsed and refractory malignancies. Chimeric antigen receptor (CAR)-T cell therapies have produced striking responses with overall remission rates of up to 90% in clinical trials. U.S. Food and Drug Administration has approved the first gene modified CAR T-cell therapy tisagenlecleucel (Kymriah) for treatment of relapsed B-cell acute lymphoblastic leukemia (ALL) in children and young adults and the second (Kymriah) for treatment of relapsed B-cell acute lymphoblastic leukemia.2 Despite this progress to generate NK cells from human pluripotent stem cells hESCs (hESC-NK) and human induced pluripotent stem cells (iPSC-NK) are becoming promising candidates to develop standardized adoptive NK cell therapy. Importantly, these cells are homogenous, feasible to genetically modify at a clonal level and easy to be expanded to clinical-scale.3,4 This review will highlight recent advances of obtaining and expanding hESC/iPSC-derived NK cells and novel genetic engineering strategies that are being applied to improve their antitumor activity (Fig. 1).

2. NK CELL BIOLOGY
NK cells are large granular lymphocytes with an intrinsic ability to kill infected and transformed cells without HLA restriction and without prior antigen sensitization.5,6 In humans, they are typically characterized as CD56+CD3− lymphocytes and can be broadly categorized in two subpopulations based on level of CD56 and CD16 expression: CD56brightCD16− cells and CD56dimCD16+ cells.7,8 The majority of PB-NK cells are CD56dimCD16+ which are highly
cytotoxic against target cells. In contrast, about 2% to 10% PB-NK cells are CD56<sup>bright</sup>CD16<sup>+</sup> which have lower cytotoxic activity while displaying a high capacity to produce immunoregulatory cytokines.<sup>22,23</sup>

NK cells can distinguish healthy cells from infected or tumor targets by the balance between inhibitory and activating signals from cell surface receptors<sup>20,24</sup>. Inhibitory signals from receptors such as killer immunoglobulin-like receptors (KIRs) and CD94-NKG2A recognize class I major histocompatibility complex (MHC) molecules which are constitutively present on normal cells to inhibit NK cell cytotoxic activity, thus preventing the killing of healthy cells.<sup>25,26</sup> NK cells can recognize and kill infected or tumor cells as these cells often lose or down regulate MHC-class I molecules, leading to the removal of inhibitory signals.<sup>27</sup> In addition, virus infected or malignant cells often up-regulate ligands which bind to NK cell activating receptors, triggering the activation of NK cells.<sup>28</sup> These activating receptors include NKG2D, KIR (activating forms), natural cytotoxicity receptors (NCRs), and CD16.<sup>29</sup>

Once activated, NK cells release preformed cytolytic granules containing granzyme and perforin to lyse tumor cells.<sup>30</sup> NK cell degranulation also occurs through antigen-dependent cellular cytotoxicity (ADCC) which is a key effector mechanism mediated by CD16.<sup>31,32</sup> Also, engaged NK cells can trigger tumor cell apoptosis through death-receptor pathways by inducing death ligands such as FAS ligand and TRAIL.<sup>33</sup> In addition, NK cells secrete proinflammatory cytokines such as interferon (IFN)-γ which also exert antitumor effects.<sup>34</sup>

3. ADOPTIVE NK CELL THERAPY

Recently, cell-based anti-cancer immunotherapies have made great advances with approval of two autologous CAR-T cell therapies (Kymryah<sup>TM</sup> and Yescarta<sup>TM</sup>) by the FDA in 2017 for treating lymphoma.<sup>1,2</sup> While CAR-T cells have attracted considerable attention, NK cells have been shown to possess potent anti-acute myeloid leukemia (AML) activity without eliciting serious adverse effects such as CRS and neurotoxicity that frequently occurs from CAR-T cell treatments.<sup>9,12</sup> Early NK cell trials used IL2 to stimulate autologous NK cells to treat hematological malignancies, metastatic melanoma, renal cell carcinoma, and advanced digestive cancer.<sup>15,16</sup> While these trials demonstrated safety with no toxic side effects, the clinical benefits were typically limited as NK cell antitumor activity was likely inhibited by self HLA molecules.<sup>15–17</sup> In contrast, clinical trials using allogeneic PB-NK cells have demonstrated that about 30% of patients with refractory or relapsed AML achieved complete remission.<sup>9,12,13,15</sup> Besides AML, allogeneic NK cell therapy has been tested for treating solid tumors,<sup>40</sup> such as ovarian, breast cancer,<sup>10</sup> lung cancers,<sup>41</sup> renal cell carcinoma, colorectal, and hepatocellular.<sup>42</sup> These studies indicate NK cells can play a therapeutic role in the treatment of solid tumors. This has led to increased interest on NK cell-based adoptive immunotherapy and explosion of NK cell-based clinical trials to treat a variety of both hematological malignancies and solid tumors.<sup>14,17,43–45</sup>

4. SOURCES OF NK CELLS USED IN CLINICAL TRIALS

To enable expanded therapeutic use of NK cells, a strategy to efficiently produce a large number of cells suitable for clinical trials is required. To date, a variety of cell sources have been used in adoptive NK cell clinical trials including PB-NK cells (both autologous and allogeneic cells), UCB-NK cells, umbilical cord blood CD34+ cell-derived NK cells (UCB-34+ NK) and the NK cell line NK-92<sup>11,12,46,47</sup> (summarized in Table 1). Although trials using these cells have demonstrated favorable safety profile, the efficacy can be modest and each cell source is confined by limitations.<sup>14,48</sup> The major limitation of using PB-NK and UCB-NK is that efficacy can be very much donor-dependent and not derived from a single renewable source. This makes it difficult to generate a standardized product and challenging to develop multi-dose treatment schema.<sup>15,49</sup> Unlike autologous CAR-T cells which were reported to persist and remain functional years beyond transplantation,<sup>50,51</sup> allogeneic NK cells typically survive only a few weeks in the adoptive transfer setting.<sup>9,10</sup> So a multi-dose treatment schema becomes necessary for adoptive NK cell therapy to maximize efficacy.<sup>15</sup> In addition, primary NK cells are in general challenging to genetically engineer due to highly variable efficiency and viability following genetic modification.<sup>52</sup> Again providing another challenge to develop consistent and reproducible genetically engineered NK cell therapies.

NK-92, a human NK cell line originally derived from a patient with lymphoma, overcomes the limitations of primary NK cells.<sup>53</sup> They are well-characterized, homogenous, easy to genetically modify and unlimited source of NK cells, which are all attractive

---

*Figure 1.* Development of standardized NK cells products using iPSC platform. Human iPSCs are reprogrammed from healthy donor tissue and can be genetically engineered to improve antitumor activities. Several strategies are being exploring to improve NK cells antitumor functions including equipping NK cells with CAR to increase cytotoxicity and target recognition, mbCD16 to enhance ADCC, mbIL15 to increase in vivo persistence and activation. A single iPSC line can be engineered with multiple components. Genetically optimized iPSCs can be stored as master cell bank to provide consistency and an essentially unlimited starting cell population to produce NK cells. iPSC-NK cells can be cryopreserved and ready to use to treating hundreds of patients, potentially with multiple doses per patient. iPSC-NK cells can be used in combination with other therapies such as anti-cancer antibodies to enable targeting of multiple tumor antigens to prevent relapse and better enable long-term remissions and cures.
properties of developing standardized NK cell therapy products. So NK-92 cells are engineered with various CARs or CD16 to increase cytotoxicity for both hematologic and solid malignancies. However, for the concern of tumorigenicity, NK-92 cells need to be irradiated prior to administration to human, which limit the antitumor activity of these cells as studies of PB-NK cells clearly show that persistence of the NK cells in patients attribute to treatment outcome.

5. NK CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS

As the technical advance of obtaining clinical scale mature NK cells from both hESCs and iPSCs, NK cells derived from human stem cells are becoming the most promising cell population for adoptive NK cell therapy. There are several advantages of using hESC-NK or iPSC-NK over primary NK cells and NK cell lines. First, hESC-NK/iPSC-NK cells are uniform, reproducible and unlimited source of NK cells which can be develop multi-dose treatment schema, eliminating the donor-to-donor variability as well as concern of limiting cell numbers when using PB-NK or UCB-NK cells. Second, it is feasible and consistent to genetically engineer hESCs and iPSCs to derive NK cells with improved antitumor activity or in vivo persistence. Diverse genome-editing technologies, such as, lentivirus, transposons, or the CRISPR-Cas9 system can be used to engineer hESCs and iPSCs, followed by differentiating these into NK cell population.

Table 1
Sources of NK cells being used in clinical trials.

| Source of NK cells          | Stage       | Comments                                                                 | Featured ongoing clinical trials                                                                 |
|-----------------------------|-------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Autologous PB-NK cells      | Phase I or II | Well tolerated, low clinical efficacy;                                    | In combination with antibodies:                                                                  |
|                             |             | Promising results for treating AML;                                      | Plus Trastuzumab for HER2-positive Gastric Cancer (NCT02805829);                                |
|                             |             | Limited clinical efficacy for solid tumors; Hard to develop off-the-shelf products; | Plus Rituximab for B Lymphoma (NCT02843061);                                              |
|                             |             | Challenge to improve efficacy through gene editing                      | Plus Cetuximab for recurrent Non-small Cell Lung Cancer (NCT02845856);                        |
|                             |             |                                                                          | Plus anti-GD2 for Relapsed Refractory Neuroblastoma (NCT02573896, NCT03242603);               |
|                             |             |                                                                          | As adjuvant therapy with chemotherapy (NCT02734524 and NCT03410368);                         |
| Allogeneic PB-NK cells      | Phase I or II | Well tolerated, Promising results for treating AML;                      | In combination with antibodies or ALT803 (IL15 superagonist);                                   |
|                             |             | Limited clinical efficacy for solid tumors; Hard to develop off-the-shelf products; | Plus anti-GD2 for High-Risk Neuroblastoma (NCT02650648);                                     |
|                             |             | Challenge to improve efficacy through gene editing                      | Combine with ALT803 for multiple cancers (NCT02800758);                                        |
|                             |             |                                                                          | Stimulation with cytokines or small molecules;                                                 |
|                             |             |                                                                          | Adaptive NK cells (FATE-NK100, stimulated with GSK3 inhibitor) for AML, ovarian cancer and other solid tumors (NCT03210364, NCT03319459, NCT03081780); |
|                             |             |                                                                          | CAR-NK NKG2D-Ligand targeted CAR-NK Cells for metastatic solid tumors (NCT03415100);           |
| Allogeneic UCB-NK cells     | Phase I or II | Difficult to develop off-the-shelf products; Difficult to manufacture large numbers of genetically modified NK cells | In combination with antibodies                                                                  |
|                             |             |                                                                          | Plus Rituximab for B-cell Lymphoma (NCT03019640);                                             |
|                             |             |                                                                          | Plus Eotuzumab for Multiple Myeloma (NCT01729001);                                            |
|                             |             |                                                                          | CAR-NK CD19-CAR-IL15 for B-cell Lymphoma (NCT03579927)                                         |
|                             |             |                                                                          | CD19-CAR for B cell lymphoma (NCT03056339);                                                   |
| NK92 cells                  | Phase I     | Easy to expand and                                                       | CAR-NK NK92-CAR targeting CD33 for Relapsed/Refractory CD33+ AML (NCT02944162);                 |
|                             |             | Can be developed as off-the-shelf products;                            | NK92-CAR targeting HER2 for Recurrent HER2-positive Glioblastoma (NCT03383978);                  |
|                             |             | Feasible to constantly genetic modify;                                 | Monotherapy and in Combination With Monoclonal Antibody (NCT03841110);                        |
|                             |             | Safe after irradiation but low efficacy if without gene modification    | CAR-NK Engineered with Novel CD16 Fc Receptor (FATE FT516)                                      |
| NK cells derived from stem cells | Phase I    | Easy to expand and                                                       | Unmodified iPSC derived NK cells                                                               |
|                             |             | Can be developed as off-the-shelf products;                            | Monotherapy and in Combination With Monoclonal Antibody (NCT03841110);                        |
|                             |             | Feasible to constantly genetic modify;                                 | CAR-NK Engineered with Novel CD16 Fc Receptor (FATE FT516)                                      |
|                             |             | Don’t need to irradiate before administration thus should have good in vivo survival and expansion | Monotherapy and in Combination With Monoclonal Antibody (NCT03841110);                        |

Zhu and Kaufman
media supplemented with SCF, Fms-like tyrosine kinase 3 ligand (FLT3L), IL-3, IL-15, IL-7 to direct differentiation towards CD45+CD56+ NK cells.17 NK cells generated using this method have demonstrated mature phenotypes and functionalities similar to primary NK cells.16,17 They can kill diverse hematologic and solid tumor cell lines in vitro and eliminated leukemia cells (K562 cells) xenografted in immune-deficient mice.17 Interestingly, hESC-derived NK cells showed better antitumor activity than UCB-34+ NK cells which were typically phenotypically immature.17,18 To produce hESC and iPSC-derived NK cells with more clinically compatible conditions and at a scale suitable for clinical trials, our group adopted a “spin-EB” protocol that eliminated the use of stromal cell lines and FBS.19,66 These serum-free, stromal-free conditions produce even more CD34+CD45+ hematopoietic progenitor cells than the stroma plus FBS conditions used previously.18 The EBs containing hematopoietic progenitor cells can be transferred without sorting to either stromal cells (OP9-DL4) or uncoated plates in serum-free media supplemented with cytokines to effectively produce mature CD45+CD56+ NK cells. Indeed, EBs on uncoated plates can form adherent cells to support attachment and differentiation, making the entire process from stem cells to mature NK cells serum-free and stromal-free which are attractive for clinical applications.67 Using these conditions, functional NK cells have been effectively produced from multiple different hESC and iPSC lines.59 Recently, we further improved this method by adapting the mouse embryonic fibroblast-dependent hESC/iPSC to feeder-free culture conditions and including Rho-associated protein kinase inhibitor (ROCKI) during EB formation.68 To expand hESC-NK and hiPSC-NK cells to a clinical-grade, a K562-based artificial antigen-presenting cells (aAPCs) expressing membrane-bound IL-21 (mIL21) have been used.58 These aAPCs have been used to propagate clinical-grade PB-NK cells for human trials of adoptive immunotherapy. These conditions can routinely produce >10^7 CD45+CD56+ NK cells from 10^6 starting undifferentiated hESCs or hiPSCs.19 Since clinical protocols of PB-NK cells or UCB-NK cells typically use doses of approximately 10^7 NK cells per kg, in vitro differentiation protocol developed by our group plus expansion system can effectively be used for clinical-grade NK cell production.13 hESC-NK and hiPSC-NK cells express a typical repertoire of activating and inhibitory receptors found on PB-NK or UCB-NK cells and effectively kill both hematological malignancies and solid tumor cells.6,13 More importantly, hESC-NK and hiPSC-NK cells are effective against leukemia and ovarian cancer without any evidence of teratomas or other untoward effects in xenograft tumor models in vivo.17,59,61 Additional studies also showed hESC-NK and hiPSC-NK cells both were able to inhibit HIV-infection in vitro and in vivo.70

6. GENETIC MODIFICATIONS OF HIPSC-NK CELLS TO ENHANCE ANTITUMOR FUNCTIONS

Despite the increasing interest on using adoptive NK cell therapy for treating cancers, the efficacy in human trials have been limited especially for solid tumors.10 One of the major reasons is the adoptive transfer of primary NK cells or irradiated NK-92 cells demonstrate low persistence in vivo that limits their antitumor efficacy.40,71 In addition, the tumor microenvironment could cause NK cell exhaustion and dysfunction through several different mechanisms.72,73 For instance, many immune-suppressive cytokines and metabolites such as TGF-β, prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), and adenosine produced by tumor cells in the tumor microenvironment could suppress the proliferation and function of NK cells.74,76 Moreover, the tumor microenvironment is rich in other host immune cells such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Treg cells) that can be activated by IL2 to inhibit NK cell function and limit their antitumor activity.38,74 Finally, NK cells without genetic modifications have low or no cytotoxicity against some tumor targets such as B cell lymphoma and choriocarcinoma cell, likely due to lack of ligands for NK cell activating receptors and high expression of inhibitory ligands. Thus, improving NK cell in vivo persistence, overcoming the immunosuppressive tumor environment and potentiating antitumor cytotoxicity through genetic modifications are highly desirable for improving NK cell antitumor activity and developing next generation adoptive NK cell therapy products.71 However, as noted, NK cells currently used in clinical trials can be hard to consistently genetically modify (primary NK cells) or have to be irradiated (NK-92 cells) before administration to human. In contrast, hESC/iPSC-derived NK cells are homogeneous and readily able to be genetically modified to provide an ideal cell population to develop standardized immunotherapy products (Fig. 1). The following section highlights the strategies are being explored to enhance antitumor functions of hiPSC-NK cells.

7. ENGINEERING HIPSC-NK CELLS WITH CAR TO ENHANCE TUMOR ACTIVITY

CARs on different source of NK cells such as PB-NK, UCB-NK, and NK92 cells have been recently explored to direct antitumor activity.77,78 CAR engineering NK-92 cells targeting a serial of antigens including CD19, CD20, ErbB2 (HER2), CD38, EGFR, GD2, and so on have shown promising results in preclinical in vivo models.53 In addition, UCB-NK cells engineered with CAR-CD19, IL-15 and inducible caspase-9 suicide (ic9) gene have shown improved persistence and antitumor activity in a Raji lymphoma mouse models.48 These preclinical proof of concepts studies have led to clinical testing of CAR-NK cells for the treatment of both hematological malignancies and refractory solid tumors.77 However, these trials all utilize CARs designed for T cells and not optimized for NK cell signaling.

Our group engineered iPSC-NK cells with a novel CAR containing the transmembrane domain of NKG2D, the 2B4 co-stimulatory domain, and the CD3ζ signaling domain to mediate strong antigen-specific NK cell signaling.61 This NK-CAR was specifically designed to enhance NK cell activity targeting mesothelin-expressing tumors.61,80 In an ovarian cancer xenograft model, NK-CAR expressing iPSC-NK cells significantly inhibited tumor growth and prolonged survival in comparison with PB-NK cells, unmodified iPSC-NK cells, or iPSC-NK cells expressing T CAR (CD28-41BBζ). Interestingly, in the same in vivo model, NK-CAR expressing iPSC-NK cells showed higher persistence in circulation, spleen, and peritoneal fluid compared with PB-NK cells and iPSC-NK cells at 10 days after intraperitoneal injection. Furthermore, comparison of third-generation T-CAR-expressing T cells to CAR-expressing NK cells in an ovarian cancer xenograft model suggested that CAR-expressing NK cells can exert antitumor effects in a safer way compared with T-CAR-expressing primary T cells.61 Using this CAR targeting other antigens is underway.81 CAR-targeted hiPSC-NK cells in combining with platform of clinical-scale production of iPSC-derived NK cells are enabling clinical trials for treatment of refractory malignancies.
8. ENGINEERING HIPSC-NK CELLS WITH CD16 TO ENHANCE ADCC

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a key effector mechanism used by NK cells enabling the antitumor effect of therapeutic mAbs. This process is mediated by CD16a, which binds the Fc portion of antibodies. Interestingly, CD16a is cleaved by the metalloprotease ADAM17 that is produced by both tumor cells and activated NK cells. CD16a has two single nucleotide polymorphism (SNP) variants, the high Fc affinity FcyRIIa158V and low affinity FcyRIIa158F. Patients with the CD16a high affinity SNP treated with cetuximab, trastuzumab, or rituximab have been shown to have greater objective response and progression free survival than patients with the low affinity SNP. When NK cells are activated, the CD16a molecule is cleaved from the surface of activated NK cells by ADAM17 expressed on the surface of both tumors and NK cells, leading to reduced ADCC capacity during mAb therapy. Our group and others previously identified the ADAM17 cleavage site of CD16a and created a non-cleavable version of CD16a by mutating the cleavage site. By engineering hiPSC-NK cells with CD16 that also contains the ADAM17-resistant point mutation, a high affinity, non-cleavable version of CD16 (hnCD16) can be expressed on ipSC-derived NK cells to prevent activation induced shedding upon stimulation thus exhibit enhanced ADCC against various tumor targets in vitro and in xenograft mouse models. The beauty of engineering hiPSC-NK cells with hnCD16 is that the modified NK cells could be combined with essentially any readily available antitumor antibodies and universally targeted to diverse tumors without need to engineer them with CARs-specific to each tumor antigen. Notably, it is also feasible to integrate hnCD16 to CAR expressing hiPSC-NK cells to further improve NK cell functions and possibly target multiples antigens simultaneously by combing with antibodies or CARs.

9. ENGINEERING HIPSC-NK CELLS WITH IL15 SIGNALING TO IMPROVE PERSISTENCE AND FUNCTION

Cytokines such as IL2 and IL15 are key stimulators of NK cell activity, including differentiation, proliferation, activation, and survival. IL2 has been widely used to expand NK cells in vitro and prolong NK cell survival after administration to patients. However, IL2 can cause adverse effects such as capillary leak syndrome in patients. Also, IL2 activates T-reg cells which in turn inhibit NK cell function and decrease its anticancer effect. IL15 has been shown to stimulate NK cell proliferation and IL-15 levels correlated with in vivo expansion of infused NK cells in patients. In nonhuman primates, IL15 stimulate NK cell expansion without exerting apparent toxicities. Notably, IL15 does not activate T-Reg cells. Thus, IL15 may hold more promise compared with IL2 to support NK cell-based therapies. Several IL-15 products are in clinical development including the IL-15 superagonist (ALT 803). ALT-803 was shown to be well tolerated by patients and was able to promote CD8+ T and NK cell expansion in vivo without stimulating Treg cells. In physiological condition, endogenous IL-15 in serum binds to IL-15Rα to form a natural complex which is trans-presented to cells expressing the dimeric IL-15β (CD122)/γc (CD132) receptor including NK cells. Upon binding to IL-15β and γc subunits, IL15 activates Janus kinase 1 (Jak1) and Janus kinase 3 (Jak3), which leads to phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3) and STAT5.

One group created a membrane-bound IL15 (mbIL15) by linking human IL15 gene to that encoding CD8α and transduced to PB-NK cells. They showed that human NK cells expressing mbIL15 survival and expansion better in vitro and in vivo without exogenous cytokines than unmodified NK cells or NK cells expressing non-membrane bound IL-15. In addition, mbIL15 NK cells exhibited enhanced cytotoxicity against leukemia, lymphoma and solid tumor cells in vitro, and against leukemia and sarcoma cells in xenograft models. Recently, another group created a different mbIL15 by fusing IL15 and IL15R with a Ser-Gly linker and co-expressed with second generation CAR in T cells using the Sleeping Beauty (SB) system. mbIL15-CAR T cells exhibited improved persistence and antitumor effects in leukemia xenograft models. Interestingly, the long-term persistent mbIL15-CAR T cells show memory stem-cell phenotype (CD45RO–negCCR7+CD95+) We and our collaborators engineered hiPSC-NK cells with NK-CAR against CD19 and mbIL15 and showed significantly increased expansion rate in the absence of cytokines in vitro.

Another way to potentiate cytokine signaling in NK cells is to modulate negative regulators of cytokine signaling. The suppressor of cytokine (SOCS) proteins (CIS; SOCS1-7) are reported to be important negative regulators of cytokine signaling, and CIS has been shown to be a potent inhibitory checkpoint in NK cell-mediated tumor immunity as deletion of CIS in mouse NK cells made them hypersensitive to IL-15 and enhanced cytotoxicity toward tumors. Deletion of CIS in iPSCK cells demonstrated CIS could regulate antitumor activity in human NK cells similar but not identical to that in mouse NK cells.

10. HIPSC-NK CELLS DERIVED FROM UNIVERSAL, HYPOIMMUNOGENIC HIPSC

A major challenge for adoptive cell therapy using stem cell derived products including iPSC-NK cells is the rejection of allogenic cells by the recipient’s immune system. Creating a universal and hypoimmunogenic hiPSC line which is “invisible” to immune system has recently been proposed by several groups to solve this allogeneic rejection problem. To avoid T cell mediated rejection, HLA class I surface expression has been eliminated by knocking out the accessory chain beta-2-microglobulin (B2M). However, knocking out B2M also disrupt the surface expression of non-classical HLA-E and HLA-G, which are required to prevent killing by NK cells. To prevent NK cell mediated rejection, some groups expressed HLA-E or HLA-G in B2M knockout iPSC. In addition, immune checkpoint PD-L1 and macrophage “don’t-eat me” signal CD47 were employed to create universal and hypoimmunogenic hiPSC. NK cells derived from the universal, hypoimmunogenic hiPSC line would presumably be resistant to rejection by the recipient’s immune system, thus have longer in vivo persistence. One concern for this strategy is deleting HLA might lead to loss of function in NK cells due to disarming. However, there is currently no report on studies to generate NK cells from these universal, hypoimmunogenic hiPSC lines.

11. CONCLUDING REMARKS

Recent advances in cell-based adoptive immunotherapy have revolutionized cancer treatments. Clinical trials in adoptive NK cell therapy using allogeneic PB-NK or UCB-NK and NK-92 cells
have shown to be safe and yield promising results. However, there are some obstacles of using these cells that limits the widespread use of this promising new therapy and development of off-the-shelf, standardized NK-cell products. NK cells derived from human stem cells circumvent these challenges. They can be readily genetically modified on a clonal level and provide a platform to produce uniform and consistent engineered NK cells with improved activity.

More importantly, hiPSC-NK or hESC-NK cells can be expanded into clinical-scale populations suitable to provide a standardized cellular immunotherapy product that can be used to treat hundreds or thousands of patients. NK cells genetically engineered with antigen specific CARs, enhanced CD16 signaling and mBL15 in combination with antibodies targeting checkpoint inhibitors and tumor antigens hold great promise for the future of adoptive NK cell therapy.

REFERENCES

[1] First-ever CAR T-cell therapy approved in U.S. Cancer Discov 2017;7(10):911-913.
[2] FDA approves second CAR T-cell therapy. Cancer Discov 2018;8:5-6.
[3] June CH, O’Connor RS, Kawalekar OU, Ghassassi S, Milone MC. CAR T cell immunotherapy for human cancer. Science 2018;359(6382):1361-1365.
[4] Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T-cell challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 2017;9:1183-1197.
[5] Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell 2017;168(4):724-740.
[6] Ruella M, Kenderian SS. Next-generation chimeric antigen receptor T-cell therapy: going off the shelf. BioDrugs 2017;31(6):473-481.
[7] Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T-cell recognition and management. Blood 2016;127(26):3321-3330.
[8] Bonfant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 2016;3:16011.
[9] Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105(8):3051-3057.
[10] Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011;13(1):98-107.
[11] Dolstra H, Roeven MWH, Spanholtz J, et al. Successful transfer of umbilical cord blood CD34(+) hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients. Clin Cancer Res 2013;19(31):8107-8118.
[12] Romee R, Rosario M, Berrien-Elliott MM, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloproteinase-17 (ADAM17). Blood 2013;121(18):3599-3608.
[13] Jing Y, Ni Z, Wu J, et al. Identification of an ADAM17 cleavage region in human CD16 (FcgammaRIII) and the engineering of a non-cleavable version of the receptor in NK cells. PLoS One 2015;10:e0121788.
[14] Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998;188(12):2375-2380.
[15] Muller L, Aigner P, Stoiber D. Type I interferons and natural killer cell regulation in cancer. Front Immunol 2017;8:304.
[16] Sakamoto N, Ishikawa T, Kokuza S, et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med 2015;13:277.
[17] Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cell leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011;17:6287-6297.
[18] Veluchamy JP, Kok N, van der Vliet HJ, Verheul HMW, de Grujil TD, Spanholtz J. The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments. Front Immunol 2017;8:631.
[19] Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 2014;123(23):3865-3863.
[20] Yang Y, Lim O, Kim TM, et al. Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors. Cancer Immunol Res 2016;4:215-224.
[21] Dahlberg CI, Sarhan D, Chrobok M, Duru AD, Alici E. Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity. Front Immunol 2015;6:605.
[22] Biopoulou EG, Kontourakis P, Karamouzis MV, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010;59(12):1781-1789.
[23] Barkholt L, Alici E, Conrad R, et al. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy-UK 2009;1(3):743-764.
[24] Handgretinger R, Lang P, Andre MC. Exploitation of natural killer cells for the treatment of acute leukemia. Blood 2016;127(26):3341-3349.
[25] Johnson JK, Miller JS. Current strategies exploiting NK-cell therapy to treat haematologic malignancies. Int J Immunogenet 2018;45:237-246.
[26] Miller JS, Lanier LL. Natural killer cells in cancer immunotherapy. Annu Rev Cancer Biol 2019;3:77-103.
Zhu and Kaufman

[46] Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered to express chimeric antigen receptor CD47 show long-term persistence and potent antitumor activity. *Leukemia* 2018;32:520–531.

[47] Williams BA, Law AD, Routy B, et al. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. *OncoTARGET* 2017;8(13):18926–19268.

[48] Cooley S, Weisdorf DJ, Gaethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. *Blood* 2010;116:2411–2419.

[49] Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. *Leukemia* 2004;18:1835–1838.

[50] Ritchie DS, Neeson PJ, Khet A, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. *Mol Ther* 2013;21(11):2122–2129.

[51] Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cell therapy for B-cell acute lymphoblastic leukemia. *Proc Natl Acad Sci U S A* 2013;110(36):14711–14716.

[52] nuevo DS, Gehrke A, Sipes P, et al. Screening of mouse mAbs according to their ADCC potential. *Cell Immunol* 2001;212(1):15–20.

[53] Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose hematopoietic cell transplantation. *Blood* 2010;116:6101–6119.

[54] Cooley S, Weisdorf DJ, Gaethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. *Blood* 2010;116:2411–2419.

[55] Romee R, Cooley S, Berrien-Elliott MM, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. *Blood* 2018;131(23):2515–2527.

[56] Ju Z, Knorr DA, Bendzick L, Allred J, Kaufman DS. Expression of chimeric antigen receptor CD47α by natural killer cells derives from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. *Stem Cells* 2014;32:1021–1031.

[57] Burga RA, Nguyen T, Zalovich J, et al. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells. *Cytotherapy* 2016;18(11):1410–1421.

[58] Hermanson DL, Ni Z, Kaufman DS. Human pluripotent stem cells as a renewable source of natural killer cells. *Front Immunol* 2017;8:533.

[59] Puri S, Soldi S, Tahara K, Kawano K, Kitano S. Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth. *J Exp Ther Oncol* 2003;6(3):336–345.

[60] Liu DF, Tian S, Zhang K, et al. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. *Protein Cell* 2017;8(12):861–877.

[61] Romanski A, Uherek C, Bug G, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. *J Cell Mol Med* 2016;20(7):1287–1294.

[62] Tao Y, Yang L, Li Z, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. *A m J Cancer Res* 2018;8:1083–1089.

[63] Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity. *Front Immunol* 2015;6:195.

[64] Lee TT, Li YE, Bjordahl R, et al. Abstract 3574: Cytokine-autonomous, CAR-directed, off-the-shelf natural killer cells from clonal engineered master pluripotent cell line. *Cancer Res* 2018;78:3574.

[65] Nimmerjahn F, Ravetch JV. Fc gamma receptors: old friends and new family members. *Immunity* 2006;24(1):19–28.

[66] Yeo WH, Wong KL, Shimasaki N, et al. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytoid. *Sci Rep* 2016;6:34310.

[67] Bibeau F, Lopez-Cravez E, Di Fiore F, et al. Impact of Fc(gamma)RIIIa polymorphism and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. *J Clin Oncol* 2009;27(7):1122–1129.

[68] Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa polymorphism. *Blood* 2002;99(3):754–758.

[69] Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. *J Clin Oncol* 2008;26(11):1789–1796.

[70] Zhu H, Bjordahl R, Gasarova S, et al. Genetically engineered pluripotent cell-derived natural killer cell therapy provides enhanced antibody dependent cellular cytotoxicity against hematologic malignancies and solid tumors in combination with monoclonal antibody therapy. *Blood* 2017;130:4452–.

[71] Huntingdon ND, Legrand N, Alves NL, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. *J Exp Med* 2009;206(1):25–34.

[72] Lehmann G, Zeis M, Uhler M. Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. *Br J Haematol* 2001;114(3):660–665.

[73] Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. *Oncology-Ny* 2002;16(11 Suppl 13):11–20.

[74] Ghiringhelli F, Menard C, Terme M, et al. CD4(+) CD25(+) regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. *J Exp Med* 2005;202(8):1075–1085.

[75] Berger C, Berger M, Hackman RC, et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. *Blood* 2009;114(12):2417–2426.

[76] Romee R, Cooley S, Berrien-Elliot MM, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. *Blood* 2018;131(23):2515–2527.
Mathios D, Park CK, Marcus WD, et al. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. *Int J Cancer* 2016;138(1):187–194.

Tamzalit F, Barbieux I, Plet A, et al. IL-15/IL-15R alpha complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells. *Proc Natl Acad Sci USA* 2014;111(8):565–570.

Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health and in cancer. *Clin Cancer Res* 2014;20(8):2044–2050.

Imamura M, Shook D, Kamiya T, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. *Blood* 2014;124(7):1081–1088.

Hurton LV, Singh H, Najjar AM, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumorspecific T cells. *Proc Natl Acad Sci USA* 2016;113(48):E7788–E7797.

Keating N, Nicholson SE. SOCS-mediated immunomodulation of natural killer cells. *Cytokine* 2018;29609875.

Delconte RB, Kolesnik TR, Dagley LF, et al. Cis is a potent checkpoint in NK cell-mediated tumor immunity. *Cytokine* 2016;87:153–154.

Zhu H, Blum R, Wu Z, et al. Notch activation rescues exhaustion in CISH-deleted human iPSC-derived natural killer cells to promote in vivo persistence and enhance anti-tumor activity. *Blood* 2018;132(12):1279.